The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: cyclodextrin drug conjugates. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.
See Also:
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
80+ innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, engineered multispecific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Cyclodextrin drug conjugates is a key innovation area in the pharmaceutical industry
Cyclodextrins (CDs) are polysaccharides formed by biodegrading starch using glucanotransferase enzyme. They are obtained in three different forms – alpha-CD, beta-CD, and gamma-CD. CDs are used where an encapsulation application is required for a pharmaceutical agent as they can host active molecules through their internal hydrophobic cavities. CDs also help in masking and prolonging the half-life of drugs used in the treatment of cancer.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 120+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of cyclodextrin drug conjugates.
Key players in cyclodextrin drug conjugates – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to cyclodextrin drug conjugates
| Company | Total patents (2010 - 2022) | Premium intelligence on the world's largest companies |
| Axsome Therapeutics | 144 | Unlock Company Profile |
| Ligand Pharmaceuticals | 92 | Unlock Company Profile |
| Zhejiang Jiuzhou Pharmaceutical | 61 | Unlock Company Profile |
| Bristol-Myers Squibb | 47 | Unlock Company Profile |
| Sapiotec | 38 | Unlock Company Profile |
| Jurox | 37 | Unlock Company Profile |
| Galderma | 32 | Unlock Company Profile |
| Alcon | 30 | Unlock Company Profile |
| Indus Biotech | 29 | Unlock Company Profile |
| Sage Therapeutics | 29 | Unlock Company Profile |
| AiVita Biomedical | 26 | Unlock Company Profile |
| Pierre Fabre Foundation | 25 | Unlock Company Profile |
| Chiesi Farmaceutici | 25 | Unlock Company Profile |
| Centre National de la Recherche Scientifique | 25 | Unlock Company Profile |
| Roquette Freres | 24 | Unlock Company Profile |
| Bayer | 23 | Unlock Company Profile |
| Midatech Pharma | 22 | Unlock Company Profile |
| Bausch Health Companies | 15 | Unlock Company Profile |
| Foresee Pharmaceuticals | 15 | Unlock Company Profile |
| Novo Nordisk Foundation | 14 | Unlock Company Profile |
| Altergon | 14 | Unlock Company Profile |
| Melinta Therapeutics | 14 | Unlock Company Profile |
| Wockhardt | 14 | Unlock Company Profile |
| Universal Technical Institute | 14 | Unlock Company Profile |
| Poli Md | 12 | Unlock Company Profile |
| BC Partners | 12 | Unlock Company Profile |
| UCB | 11 | Unlock Company Profile |
| Otsuka | 11 | Unlock Company Profile |
| Golden Omega | 11 | Unlock Company Profile |
| OP2 Drugs | 11 | Unlock Company Profile |
| Aurea Biolabs | 10 | Unlock Company Profile |
| Biocydex | 10 | Unlock Company Profile |
| Takeda Pharmaceutical | 10 | Unlock Company Profile |
| Rezolute | 9 | Unlock Company Profile |
| Erimos Pharmaceuticals | 9 | Unlock Company Profile |
| RaQualia Pharma | 9 | Unlock Company Profile |
| Fondazione Istituto Insubrico di Ricerca per la Vita | 8 | Unlock Company Profile |
| Asdera | 8 | Unlock Company Profile |
| Lundbeck | 8 | Unlock Company Profile |
| AskAt | 8 | Unlock Company Profile |
| E. Merck | 8 | Unlock Company Profile |
| Meridian Laboratories | 8 | Unlock Company Profile |
| H. Lundbeck | 7 | Unlock Company Profile |
| Dr. Reddy's Laboratories | 7 | Unlock Company Profile |
| Jointherapeutics | 7 | Unlock Company Profile |
| Teva Pharmaceutical Industries | 7 | Unlock Company Profile |
| Sefacor | 6 | Unlock Company Profile |
| Bayer Pharma (Bayer Schering Pharma) | 6 | Unlock Company Profile |
| Merck | 6 | Unlock Company Profile |
| Consejo Superior Investigacion | 6 | Unlock Company Profile |
Source: GlobalData Patent Analytics
Axsome Therapeutics is the leading patent filer in cyclodextrin drug conjugates. Axsome Therapeutics is a biopharmaceutical company that develops and commercializes therapies for the treatment of central nervous system (CNS) disorders. Axsome is headquartered in New York, US.
In terms of application diversity, Takeda Pharmaceutical is the top company, followed by Zhejiang Jiuzhou Pharmaceutical and Bristol-Myers Squibb. By means of geographic reach, Jurox holds the top position. While Alcon and Sage Therapeutics stand in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
